{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:41:43Z","timestamp":1784238103712,"version":"3.55.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1053\/j.seminhematol.2024.06.003","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T18:03:00Z","timestamp":1719597780000},"page":"253-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era"],"prefix":"10.1053","volume":"61","author":[{"given":"Gaurav","family":"Varma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1116-3246","authenticated-orcid":false,"given":"Catherine","family":"Diefenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1053\/j.seminhematol.2024.06.003_bib0001","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.003_bib0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial","volume":"42","author":"Luminari","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.003_bib0003","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"8852","key":"10.1053\/j.seminhematol.2024.06.003_bib0004","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"9323","key":"10.1053\/j.seminhematol.2024.06.003_bib0005","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.06.003_bib0006","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.003_bib0007","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","author":"Rancea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.06.003_bib0008","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood.V126.23.2736.2736","article-title":"Five-year survival data demonstrating durable responses from a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory hodgkin lymphoma","volume":"126","author":"Chen","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.06.003_bib0009","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.06.003_bib0010","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.06.003_bib0011","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","article-title":"Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant","volume":"54","author":"Arai","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.06.003_bib0012","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1992.10.2.210","article-title":"Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure","volume":"10","author":"Longo","year":"1992","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.06.003_bib0013","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood.V77.10.2292.2292","article-title":"Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988","volume":"77","author":"Lohri","year":"1991","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.003_bib0014","first-page":"423","article-title":"Role of chemoresistance prior to autologous bone marrow transplantation for Hodgkin's disease","volume":"36","author":"Voillat","year":"1994","journal-title":"Nouv Rev Fr Hematol (1978)"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.06.003_bib0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/JCO.1989.7.2.179","article-title":"Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease","volume":"7","author":"Jagannath","year":"1989","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.003_bib0016","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.06.003_bib0017","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3109\/10428194.2013.854888","article-title":"Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant","volume":"55","author":"von Tresckow","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.003_bib0018","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.06.003_bib0019","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V89.3.801","article-title":"High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices","volume":"89","author":"Horning","year":"1997","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.06.003_bib0020","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.06.003_bib0021","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3109\/10428194.2011.573889","article-title":"Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma","volume":"52","author":"Mocikova","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.003_bib0022","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1365-2141.2009.08037.x","article-title":"High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging","volume":"148","author":"Moskowitz","year":"2010","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.06.003_bib0023","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"27","key":"10.1053\/j.seminhematol.2024.06.003_bib0024","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.06.003_bib0025","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.06.003_bib0026","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease","volume":"13","author":"Josting","year":"2002","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.003_bib0027","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.003_bib0028","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"issue":"27","key":"10.1053\/j.seminhematol.2024.06.003_bib0029","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase ii study","volume":"34","author":"Santoro","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.003_bib0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/bloodadvances.2019000984","article-title":"Five-year results of the BEGEV salvage regimen in relapsed\/refractory classical Hodgkin lymphoma","volume":"4","author":"Santoro","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.06.003_bib0031","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase ii trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.06.003_bib0032","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdx791","article-title":"Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"29","author":"Herrera","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.06.003_bib0033","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.06.003_bib0034","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.06.003_bib0035","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1080\/10428194.2022.2107204","article-title":"Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory\/relapsed Hodgkin lymphoma: a lymphoma study association phase I\/II study","volume":"63","author":"Stamatoullas","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.003_bib0036","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study","volume":"106","author":"Kersten","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.003_bib0037","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.06.003_bib0038","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41409-019-0454-z","article-title":"Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma","volume":"54","author":"Abuelgasim","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.06.003_bib0039","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/blood.V126.23.2479.2479","article-title":"Continuous Exposure to Bendamustine (BDM) Results in Stable Upregulation of CD30 and Increased Sensitivity to Brentuximab Vedotin (BV) in Tumor Cells of Hodgkin Lymphoma (HL)","volume":"126","author":"De Filippi","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.003_bib0040","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.003_bib0041","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.06.003_bib0042","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-019-0265-x","article-title":"First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi","volume":"9","author":"Broccoli","year":"2019","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.06.003_bib0043","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"19","author":"O'Connor","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.06.003_bib0044","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/bjh.16499","article-title":"Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma","volume":"189","author":"LaCasce","year":"2020","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.06.003_bib0045","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.003_bib0046","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-21-2023","article-title":"Tislelizumab for relapsed\/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis","volume":"28","author":"Song","year":"2022","journal-title":"Clin Canc Res"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.06.003_bib0047","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A single-arm, multicenter, Phase II Study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Canc Res"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.06.003_bib0048","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/bloodadvances.2021004511","article-title":"Avelumab in relapsed\/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkin trial","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.003_bib0049","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2024.06.003_bib0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2021.07.021","article-title":"Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, phase II study","volume":"164","author":"Lin","year":"2022","journal-title":"Eur J Cancer"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.06.003_bib0051","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.06.003_bib0052","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"28","key":"10.1053\/j.seminhematol.2024.06.003_bib0053","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.003_bib0054","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12916-024-03329-8","article-title":"Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial","volume":"22","author":"Liu","year":"2024","journal-title":"BMC Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.003_bib0055","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.06.003_bib0056","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.06.003_bib0057","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2023-184531","article-title":"Results from an intergroup randomized phase ii study of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed\/refractory classic Hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412)","volume":"142","author":"Diefenbach","year":"2023","journal-title":"Blood"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.06.003_bib0058","first-page":"2075","article-title":"Nivolumab and brentuximab vedotin with or without bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults","volume":"141","author":"Harker-Murray","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.003_bib0059","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdi003","article-title":"Cologne high-dose sequential chemotherapy in relapsed and refractory hodgkin lymphoma: results of a large multicenter study of the German Hodgkin lymphoma study group (GHSG)","volume":"16","author":"Josting","year":"2005","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.06.003_bib0060","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ajh.26827","article-title":"Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed\/refractory classic Hodgkin lymphoma","volume":"98","author":"Desai","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.06.003_bib0061","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.06.003_bib0062","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","article-title":"Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.003_bib0063","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3324\/haematol.2021.278311","article-title":"Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis","volume":"107","author":"Nieto","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.003_bib0064","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/ejh.12737","article-title":"Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning","volume":"97","author":"Lasica","year":"2016","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.003_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.10.013","volume":"28","author":"Phelan","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.06.003_bib0066","first-page":"519","article-title":"Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma","volume":"13","author":"Chatterjee","year":"1994","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.06.003_bib0067","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4161\/cbt.26342","article-title":"Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients","volume":"14","author":"Akhtari","year":"2013","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.06.003_bib0068","first-page":"366","article-title":"The cost of hematopoietic stem-cell transplantation in the United States","volume":"10","author":"Broder","year":"2017","journal-title":"Am Health Drug Benefits"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.06.003_bib0069","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1200\/JCO.23.02547","article-title":"Clonal hematopoiesis and therapy-related myeloid neoplasms after autologous transplant for Hodgkin lymphoma","volume":"42","author":"Yan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9976","key":"10.1053\/j.seminhematol.2024.06.003_bib0070","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.06.003_bib0071","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.20.00947","article-title":"Relapse after early-stage, favorable Hodgkin lymphoma: disease characteristics and outcomes with conventional or high-dose chemotherapy","volume":"39","author":"Brockelmann","year":"2021","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.06.003_bib0072","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood.V114.22.2691.2691","article-title":"Outcome of second line therapy for pediatric patients with Hodgkin lymphoma who relapse following ABVD based therapy","volume":"114","author":"Belgaumi","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.06.003_bib0073","first-page":"883","article-title":"Outcome of first relapse of Hodgkin lymphoma: single institution experience","volume":"71","author":"Shaheen","year":"2021","journal-title":"J Pak Med Assoc"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.06.003_bib0074","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1200\/JCO.2005.07.930","article-title":"Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL\/GPOH-HD study group","volume":"23","author":"Schellong","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.003_bib0075","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.12768","article-title":"Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma\u2013results of the UK HD3 relapse treatment strategy","volume":"165","author":"Shankar","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.003_bib0076","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/bjc.1992.426","article-title":"Outcome of children with resistant and relapsed Hodgkin's disease","volume":"66","author":"James","year":"1992","journal-title":"Br J Cancer"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.06.003_bib0077","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1002\/cncr.25225","article-title":"Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients","volume":"116","author":"Metzger","year":"2010","journal-title":"Cancer"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.06.003_bib0078","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1200\/JCO.2004.02.121","article-title":"High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices","volume":"22","author":"Lieskovsky","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.003_bib0079","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1097\/HS9.0000000000000329","article-title":"Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people. recommendations from the EuroNet pediatric Hodgkin lymphoma group","volume":"4","author":"Daw","year":"2020","journal-title":"Hemasphere"},{"issue":"S1","key":"10.1053\/j.seminhematol.2024.06.003_bib0080","first-page":"1983","article-title":"P1093: brentuximab Vedotin - ESHAP significantly increases the metabolic complete remission rate versus ESHAP in relapsed classical Hodgkin's lymphoma. final results of the BRESELIBET prospective trial","volume":"8","author":"Sureda Balari","year":"2024","journal-title":"Hemasphere"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.06.003_bib0081","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2023.41.16_suppl.7515","volume":"41","author":"Harker-Murray","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.06.003_bib0082","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.HS9.0000890964.54059.2c","article-title":"T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma","volume":"6","author":"Moskowitz","year":"2022","journal-title":"Hemasphere"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.06.003_bib0083","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.3324\/haematol.2022.282266","article-title":"Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial","volume":"108","author":"Ding","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.003_bib0084","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.06.003_bib0085","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.06.003_bib0086","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/cancers15061760","article-title":"Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.06.003_bib0087","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.06.003_bib0088","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.3390\/jcm10194396","article-title":"Total lesion glycolysis improves tumor burden evaluation and risk assessment at diagnosis in Hodgkin lymphoma","volume":"10","author":"Herraez","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.003_bib0089","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2967\/jnumed.113.130609","article-title":"Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients","volume":"55","author":"Rossi","year":"2014","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.06.003_bib0090","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.06.003_bib0091","doi-asserted-by":"crossref","first-page":"e89631","DOI":"10.1172\/jci.insight.89631","article-title":"Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients","volume":"1","author":"van Eijndhoven","year":"2016","journal-title":"JCI Insight"},{"issue":"S3","key":"10.1053\/j.seminhematol.2024.06.003_bib0092","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.HS9.0000547854.66513.08","article-title":"T010 (0113) clinical validation of an extracellular vesicle associated Mirna detection assay to monitor therapy response in classical Hodgkin lymphoma patients","volume":"2","author":"Drees","year":"2018","journal-title":"Hemasphere"},{"issue":"S1","key":"10.1053\/j.seminhematol.2024.06.003_bib0093","first-page":"1985","article-title":"P1094: early detection of classic Hodgkin lymphoma relapse using routine serum TARC measurements during follow-up","volume":"8","author":"Teesink","year":"2024","journal-title":"Hemasphere"},{"issue":"S1","key":"10.1053\/j.seminhematol.2024.06.003_bib0094","first-page":"275","article-title":"S227: serum TARC combined with FDG-PET imaging improves interim response evaluation in classic Hodgkin lymphoma: a retrospective analysis of German Hodgkin Study Group HD16 and HD18 trials","volume":"8","author":"Plattel","year":"2024","journal-title":"Hemasphere"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.003_bib0095","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bjh.15585","article-title":"Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1\/2 clinical trial","volume":"183","author":"Budde","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.06.003_bib0096","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00277-014-2114-0","article-title":"ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma","volume":"93","author":"Labrador","year":"2014","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.06.003_bib0097","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","article-title":"Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Baetz","year":"2003","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.06.003_bib0098","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2141.2001.02714.x","article-title":"Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease","volume":"113","author":"Martin","year":"2001","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.06.003_bib0099","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.3324\/haematol.2018.196899","article-title":"Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed\/refractory classical Hodgkin lymphoma: The HOVON\/LLPC Transplant BRaVE study","volume":"104","author":"Hagenbeek","year":"2019","journal-title":"Haematologica"},{"issue":"S1","key":"10.1053\/j.seminhematol.2024.06.003_bib0100","first-page":"5448","article-title":"PB2915: preliminary results of the phase 2 study evaluating the safety and efficacy of pembrolizumab (Keytruda) with bendamustine (treanda) in relapsed\/refractory Hodgkin lymphoma (KEsTREL-01)","volume":"8","author":"Abeyakoon","year":"2024","journal-title":"Hemasphere"},{"issue":"S1","key":"10.1053\/j.seminhematol.2024.06.003_bib0101","first-page":"2007","article-title":"P1105: combination of brentuximab vedotin and pembrolizumab before intensification with autologous stem cell transplantation and maintenance in patients with relapsed\/refractory Hodgkin lymphoma","volume":"8","author":"Massa","year":"2024","journal-title":"Hemasphere"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T13:04:59Z","timestamp":1726837499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0037196324000805"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.06.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}